Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000663194 | SCV000786369 | likely benign | Multiple endocrine neoplasia type 2A | 2018-04-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001456357 | SCV001660135 | likely benign | Multiple endocrine neoplasia, type 2 | 2024-09-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002442386 | SCV002732276 | benign | Hereditary cancer-predisposing syndrome | 2022-03-02 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Myriad Genetics, |
RCV000663194 | SCV004018062 | likely benign | Multiple endocrine neoplasia type 2A | 2024-08-13 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant is intronic and is not expected to impact mRNA splicing. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |